What are the indications, contraindications, dosing recommendations, and monitoring parameters for glycopyrrolate (Glycop)?

Glycopyrrolate: Clinical Overview

Glycopyrrolate is a quaternary ammonium anticholinergic agent with FDA-approved indications for perioperative use (preanesthetic medication, intraoperative bradycardia, reversal of neuromuscular blockade), peptic ulcer disease, and chronic severe drooling in children aged 3-16 years with neurologic conditions. 1

FDA-Approved Indications

Perioperative Uses

• Preanesthetic medication to reduce secretions and block vagal reflexes
• Intraoperative bradycardia from drug-induced or vagal reflexes
• Reversal of neuromuscular blockade (administered with neostigmine or pyridostigmine)
• Peptic ulcer disease (though rarely used for this indication currently) 1

Chronic Drooling (Sialorrhea)

• FDA-approved oral solution (1 mg/5 mL) for chronic severe drooling in pediatric patients aged 3-16 years with cerebral palsy and other neurologic conditions 1

Dosing Recommendations

Adults - Perioperative Use 1

Preanesthetic Medication:

• 0.004 mg/kg IM, given 30-60 minutes before anesthesia induction

Intraoperative Bradycardia:

• 0.1 mg IV as single dose
• Repeat every 2-3 minutes as needed

Reversal of Neuromuscular Blockade:

• 0.2 mg for each 1.0 mg neostigmine OR 5.0 mg pyridostigmine
• Can be mixed in same syringe and given simultaneously IV

Peptic Ulcer:

• 0.1 mg IV/IM every 4 hours, 3-4 times daily
• May increase to 0.2 mg if more profound effect needed

Pediatric - Perioperative Use 1

Preanesthetic Medication:

• 0.004 mg/kg IM, given 30-60 minutes before anesthesia
• Infants (1 month to 2 years): May require up to 0.009 mg/kg

Intraoperative Use:

• 0.004 mg/kg IV, not exceeding 0.1 mg single dose
• Repeat every 2-3 minutes as needed

Reversal of Neuromuscular Blockade:

• Same as adults: 0.2 mg per 1.0 mg neostigmine or 5.0 mg pyridostigmine

Pediatric - Chronic Drooling 1, 2, 3

Oral Solution Dosing:

• Starting dose: 0.02 mg/kg PO three times daily
• Titration: Increase by 0.02 mg/kg every 5-7 days over 4 weeks
• Maximum dose: 0.1 mg/kg three times daily, not exceeding 3 mg per dose
• Typical effective dose range: 0.01-0.1 mg/kg/dose (broad individual variation) 4

The 2012 study by Zeller et al. demonstrated that 52.3% of patients achieved at least a 3-point improvement on the modified Teacher's Drooling Scale at 24 weeks, with 83.5% of caregivers rating treatment as worthwhile 3. The dose-ranging study by Mier et al. found 0.10 mg/kg per dose to be effective, though this is at the higher end of the approved range 5.

Contraindications 1

Absolute Contraindications

• Known hypersensitivity to glycopyrrolate or inactive ingredients

Additional Contraindications for Chronic Use (Peptic Ulcer/Drooling)

• Glaucoma
• Obstructive uropathy (e.g., bladder neck obstruction from prostatic hypertrophy)
• Obstructive GI disease (achalasia, pyloroduodenal stenosis)
• Paralytic ileus or intestinal atony in elderly/debilitated patients
• Unstable cardiovascular status in acute hemorrhage
• Severe ulcerative colitis or toxic megacolon
• Myasthenia gravis

Critical caveat: These contraindications apply primarily to chronic therapy. For acute perioperative use, the risk-benefit calculation differs, and glycopyrrolate may be used cautiously even in some of these conditions when the clinical situation demands it 6.

Adverse Effects and Monitoring 1, 2, 3

Common Adverse Effects (Dose-Related)

• Dry mouth (xerostomia): 9-41% in pediatric drooling studies
• Constipation: 9-39%
• Behavioral changes: 18-36% (particularly in children)
• Urinary retention/hesitancy
• Blurred vision, photophobia, mydriasis
• Flushing: 10.9%
• Nasal congestion: 10.9%

Serious Adverse Effects (Post-Marketing)

• Cardiac: Arrhythmias (bradycardia, ventricular tachycardia/fibrillation), cardiac arrest, QTc prolongation (especially with anticholinesterase agents), hypertension, hypotension
• Neurologic: Seizures, malignant hyperthermia
• Respiratory: Respiratory arrest
• Allergic: Anaphylaxis/anaphylactoid reactions

Discontinuation Rates

In the 24-week pediatric drooling study, 13.9% discontinued due to adverse events, though no single adverse event was specifically associated with discontinuation 3. Approximately 20% of children may experience adverse effects severe enough to require discontinuation 5.

Monitoring Parameters

For Chronic Use (Drooling)

• Efficacy assessment: Modified Teacher's Drooling Scale (1-9 scale) at baseline and regular intervals
• Adverse effects monitoring:
  • Dry mouth severity
  • Bowel function (constipation)
  • Behavioral changes
  • Urinary symptoms
  • Vision changes
• Vital signs: Heart rate (tachycardia)
• Laboratory: No routine monitoring required, though the 24-week study showed rare clinically significant shifts in platelet count and calcium 3

For Perioperative Use

• Continuous monitoring: Heart rate, blood pressure, respiratory rate, oxygen saturation
• ECG monitoring when used with anticholinesterase agents (risk of QTc prolongation)
• Capnography when used in procedural sedation protocols 7

Special Considerations

Pharmacokinetics 2

• Oral bioavailability: Highly variable, median 3.3%
• Tmax: 3.1 hours in children
• Half-life: 19-99 minutes in children, 22-130 minutes in infants
• Clearance: 0.6-1.43 L/kg/h in children
• Blood-brain barrier penetration: Minimal (quaternary amine structure), resulting in fewer CNS effects compared to tertiary amines like atropine 1, 8

Procedural Sedation Context

Guidelines support glycopyrrolate use in pediatric procedural sedation protocols, particularly with ketamine, to reduce secretions 7, 6. The 2004 emergency medicine guideline noted that IM ketamine/midazolam/glycopyrrolate was safe and effective for pediatric procedures 7.

Compatibility 1

• Compatible diluents: D5W, D10W, NS, D5NS 0.45%
• Incompatible: Lactated Ringer's solution
• Admixture compatible with: Neostigmine, pyridostigmine, atropine, multiple opioids and sedatives (see full list in FDA label)

Overdose Management 1

• Peripheral effects: Neostigmine 0.25 mg IV increments (adults), up to 2.5 mg total
• CNS symptoms: Physostigmine 0.5-2 mg IV slowly, up to 5 mg total
• Supportive care: IV fluids, pressors for hypotension, symptomatic fever treatment
• Respiratory support: Artificial respiration if curare-like neuromuscular blockade occurs

Benzyl Alcohol Warning 1

The injection contains benzyl alcohol, which has been associated with "gasping syndrome" in neonates. Use caution in this population.